ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
EML333
|
10K |
3.6M |
7 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
10K
|
3.6M
|
7
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
EML333
|
10K |
3.6M |
1 |
07/01/21 |
07/01/21 |
ASX - By Stock
|
10K
|
3.6M
|
1
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
EML333
|
10K |
3.6M |
0 |
07/01/21 |
07/01/21 |
ASX - By Stock
|
10K
|
3.6M
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
EML333
|
4.9K |
2.0M |
9 |
05/01/21 |
05/01/21 |
ASX - By Stock
|
4.9K
|
2.0M
|
9
|
|
ASX - By Stock
|
WBT |
Re:
Charts
|
|
EML333
|
4.9K |
2.0M |
8 |
05/01/21 |
05/01/21 |
ASX - By Stock
|
4.9K
|
2.0M
|
8
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
EML333
|
10K |
3.6M |
10 |
05/01/21 |
05/01/21 |
ASX - By Stock
|
10K
|
3.6M
|
10
|
|
ASX - By Stock
|
WBT |
Re:
QUANTUM LEAP
|
|
EML333
|
462 |
168K |
6 |
05/01/21 |
05/01/21 |
ASX - By Stock
|
462
|
168K
|
6
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
EML333
|
10K |
3.6M |
7 |
29/12/20 |
29/12/20 |
ASX - By Stock
|
10K
|
3.6M
|
7
|
|
ASX - By Stock
|
WBT |
Re:
SPP monies returned
|
|
EML333
|
39 |
13K |
2 |
26/12/20 |
26/12/20 |
ASX - By Stock
|
39
|
13K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
News Flash: 9 Analysts Think Mesoblast Limited (ASX:MSB) Earnings Are Under Threat
|
|
EML333
|
230 |
57K |
4 |
22/12/20 |
22/12/20 |
ASX - By Stock
|
230
|
57K
|
4
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit successfully completes $3 million Share Purchase Plan
|
|
EML333
|
168 |
45K |
0 |
22/12/20 |
22/12/20 |
ASX - By Stock
|
168
|
45K
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit successfully completes $3 million Share Purchase Plan
|
|
EML333
|
168 |
45K |
0 |
22/12/20 |
22/12/20 |
ASX - By Stock
|
168
|
45K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
News Flash: 9 Analysts Think Mesoblast Limited (ASX:MSB) Earnings Are Under Threat
|
|
EML333
|
230 |
57K |
6 |
22/12/20 |
22/12/20 |
ASX - By Stock
|
230
|
57K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
News Flash: 9 Analysts Think Mesoblast Limited (ASX:MSB) Earnings Are Under Threat
|
|
EML333
|
230 |
57K |
2 |
22/12/20 |
22/12/20 |
ASX - By Stock
|
230
|
57K
|
2
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit & Leti file two patents to optimise ReRAM performance
|
|
EML333
|
222 |
53K |
13 |
21/12/20 |
21/12/20 |
ASX - By Stock
|
222
|
53K
|
13
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit successfully completes $3 million Share Purchase Plan
|
|
EML333
|
168 |
45K |
2 |
21/12/20 |
21/12/20 |
ASX - By Stock
|
168
|
45K
|
2
|
|
ASX - By Stock
|
NYR |
Re:
Ann: 57% Cholesterol Reduction from NYX-PCSK9i In Vivo Study
|
|
EML333
|
37 |
10K |
1 |
21/12/20 |
21/12/20 |
ASX - By Stock
|
37
|
10K
|
1
|
|
ASX - By Stock
|
A2M |
Re:
Buying opportunity
|
|
EML333
|
305 |
139K |
6 |
19/12/20 |
19/12/20 |
ASX - By Stock
|
305
|
139K
|
6
|
|
ASX - By Stock
|
A2M |
Re:
Buying opportunity
|
|
EML333
|
305 |
139K |
2 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
305
|
139K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
EML333
|
1.0K |
517K |
9 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
EML333
|
1.0K |
517K |
1 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
EML333
|
1.0K |
517K |
1 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
EML333
|
1.0K |
517K |
1 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
1
|
|
ASX - By Stock
|
MSB Medicine |
Re:
MSB - Must Sell Bullshit
|
|
EML333
|
30 |
20K |
8 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
30
|
20K
|
8
|
|
ASX - By Stock
|
A2M |
Re:
Buying opportunity
|
|
EML333
|
305 |
139K |
6 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
305
|
139K
|
6
|
|
ASX - By Stock
|
A2M |
Re:
Buying opportunity
|
|
EML333
|
305 |
139K |
1 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
305
|
139K
|
1
|
|
ASX - By Stock
|
A2M |
Re:
Buying opportunity
|
|
EML333
|
305 |
139K |
8 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
305
|
139K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
EML333
|
1.0K |
517K |
4 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
EML333
|
1.0K |
517K |
2 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
EML333
|
1.0K |
517K |
3 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
3
|
|
ASX - By Stock
|
APT |
Re:
Afterpay Valuation
|
|
EML333
|
6.8K |
2.6M |
0 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
6.8K
|
2.6M
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano Limited - Share Purchase Plan
|
|
EML333
|
107 |
37K |
0 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
107
|
37K
|
0
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Update on UQ-CSL v451 COVID-19 Vaccine
|
|
EML333
|
58 |
29K |
2 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
58
|
29K
|
2
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano Limited - Share Purchase Plan
|
|
EML333
|
107 |
37K |
0 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
107
|
37K
|
0
|
|
ASX - By Stock
|
CSL |
Re:
Ann: Update on UQ-CSL v451 COVID-19 Vaccine
|
|
EML333
|
58 |
29K |
0 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
58
|
29K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
EML333
|
572 |
251K |
5 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
251K
|
5
|
|
ASX - By Stock
|
WBT |
Re:
Weebit - 2021and beyond
|
|
EML333
|
10K |
3.6M |
0 |
01/12/20 |
01/12/20 |
ASX - By Stock
|
10K
|
3.6M
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano secures $12m to accelerate growth momentum
|
|
EML333
|
552 |
146K |
12 |
25/11/20 |
25/11/20 |
ASX - By Stock
|
552
|
146K
|
12
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano secures $12m to accelerate growth momentum
|
|
EML333
|
552 |
146K |
13 |
25/11/20 |
25/11/20 |
ASX - By Stock
|
552
|
146K
|
13
|
|
ASX - By Stock
|
DCC |
Re:
Ann: First RegTech product for publicly traded entities launched
|
|
EML333
|
65 |
27K |
1 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
65
|
27K
|
1
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Trading halt
|
|
EML333
|
483 |
161K |
6 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
483
|
161K
|
6
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene HER Vaxx shows positive Overall Survival in trial
|
|
EML333
|
254 |
111K |
24 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
254
|
111K
|
24
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene HER Vaxx shows positive Overall Survival in trial
|
|
EML333
|
254 |
111K |
24 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
254
|
111K
|
24
|
|
ASX - By Stock
|
WBT |
Re:
WBT and Silicon Oxide competition
|
|
EML333
|
38 |
13K |
5 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
38
|
13K
|
5
|
|
ASX - By Stock
|
WBT |
Re:
WBT and Silicon Oxide competition
|
|
EML333
|
38 |
13K |
1 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
38
|
13K
|
1
|
|
ASX - By Stock
|
WBT |
Re:
WBT and Silicon Oxide competition
|
|
EML333
|
38 |
13K |
4 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
38
|
13K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
EML333
|
811 |
334K |
1 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
334K
|
1
|
|
Charts
|
APT |
Re:
APT Chart
|
|
EML333
|
4.6K |
1.8M |
2 |
10/11/20 |
10/11/20 |
Charts
|
4.6K
|
1.8M
|
2
|
|
Charts
|
APT |
Re:
APT Chart
|
|
EML333
|
4.6K |
1.8M |
1 |
10/11/20 |
10/11/20 |
Charts
|
4.6K
|
1.8M
|
1
|
|
Charts
|
APT |
Re:
APT Chart
|
|
EML333
|
4.6K |
1.8M |
0 |
10/11/20 |
10/11/20 |
Charts
|
4.6K
|
1.8M
|
0
|
|